Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study
Tiago Torres, L. Puig, Ronald Vender, Jensen Yeung, J.M. Carrascosa, Stefano Piaserico, Paolo Gisondi, Charles Lynde, Paulo Ferreira, Pedro Mendes‐Bastos, E. Daudén, Luíz Leite, Joana Valério, E. del Alcázar-Viladomiu, E. Vilarrasa Rull, Mar Llamas‐Velasco, Federico Pirrò, Francesco Messina, Manfredo Bruni, Gaetano Licata, Federica Ricceri, Alessia Nidegger, Jan Hugo, Asfandyar Mufti, A. Daponte, Laetitia Teixeira, Anna Balato, Marco Romanelli, Francesca Prignano, Spyridon Gkalpakiotis, Curdin Conrad, Elizabeth Lazaridou, Natalia Rompoti, Marina Papoutsaki, Miguel Nogueira, Andrea Chiricozzi
Topics & Concepts
MedicineSecukinumabHazard ratioInternal medicineIxekizumabRetrospective cohort studyDiscontinuationProportional hazards modelPsoriasisCohortConfidence intervalPsoriatic arthritisImmunologyArthritisPsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsHidradenitis Suppurativa and Treatments